← Every company
Ionis Pharmaceuticals Inc Patents
What Ionis Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
IONS on carbonthat →Filings on file
58
Granted
1
Still pending
57
Filed under
2 names
58 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| Methods for Reducing HTT ExpressionA61K 48/00, C12N 15/113, A61P 25/14, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/3341, C12N2310/341, C12N2320/35, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2026-04-27C. Frank Bennett | pending |
| Compounds and Methods for Reducing KCNT1 ExpressionC12N 15/1138, C12N2310/11, C12N2310/315, C12N2310/322, C12N2310/3341, C12N2310/341, C12N2310/345, C12N2310/346, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2026-04-20Paymaan Jafar-nejad | pending |
| Compounds and Methods for Reducing ATXN3 ExpressionC12N 15/113, C12N 15/1137, A61P 25/28, A61K 31/7088, C12N2310/11, C12N2310/311, C12N2310/315, C12N2310/322, C12N2310/3341, C12N2310/341, C12N2310/346, C12N2320/11, C12N2320/30, C12N2320/53, C12N2310/321, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2026-03-13Susan M. Freier | pending |
| MODIFIED OLIGONUCLEOTIDESFiled as IONIS PHARMACEUTICALS, INC.2026-03-12GRAEME C. FREESTONE | pending |
| POLYPEPTIDES AND USES THEREOFFiled as IONIS PHARMACEUTICALS, INC.2026-03-12TODD MICHAEL | pending |
| Compositions for Modulating Ataxin 2 ExpressionC12N 15/113, A61P 21/00, A61P 25/28, A61P 25/00, A61P 25/16, A61K 31/7088, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/3231, C12N2310/3341, C12N2310/341, C12N2310/345, C12N2310/346, C12N2310/352, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2026-02-20Susan M. Freier | pending |
| Compositions for Modulating C9ORF72 ExpressionA61K 31/7125, C12N 15/113, A61P 25/28, A61P 43/00, A61P 25/00, A61P 25/16, C12N2310/11, C12N2310/313, C12N2310/315, C12N2310/322, C12N2310/3233, C12N2310/3341, C12N2310/341, C12N2310/346, C12N2310/3525, C12N2310/3533Filed as Ionis Pharmaceuticals, Inc.2026-01-29C. Frank Bennett | pending |
| CONJUGATED ANTISENSE COMPOUNDS AND THEIR USEA61K 47/549, A61K 31/7125, C12N 15/113, A61K 47/59, A61P 43/00, A61P 3/00, A61P 9/00, A61P 25/00, A61K 31/7088, A61K 31/7105, A61K 31/713, A61K 48/00, C07H 21/00, C07H 21/04, C12N 15/111, C12N 15/1137, C12N2310/11, C12N2310/113, C12N2310/14, C12N2310/17, C12N2310/31, C12N2310/315, C12N2310/32, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/3341, C12N2310/34, C12N2310/341, C12N2310/346, C12N2310/35, C12N2310/351, C12N2310/3511, C12N2310/3513, C12N2310/3515, C12N2310/3525, C12N2310/353, C12N2320/32, C12Y 301/03048Filed as Ionis Pharmaceuticals, Inc.2026-01-27Thazha P. Prakash | pending |
| CONJUGATED ANTISENSE COMPOUNDS AND THEIR USEA61K 47/549, A61K 31/7125, C12N 15/113, A61K 47/59, A61P 43/00, A61P 3/00, A61P 9/00, A61P 25/00, A61K 31/7088, A61K 31/7105, A61K 31/713, A61K 48/00, C07H 21/00, C07H 21/04, C12N 15/111, C12N 15/1137, C12N2310/11, C12N2310/113, C12N2310/14, C12N2310/17, C12N2310/31, C12N2310/315, C12N2310/32, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/3341, C12N2310/34, C12N2310/341, C12N2310/346, C12N2310/35, C12N2310/351, C12N2310/3511, C12N2310/3513, C12N2310/3515, C12N2310/3525, C12N2310/353, C12N2320/32, C12Y 301/03048Filed as Ionis Pharmaceuticals, Inc.2026-01-27Thazha P. Prakash | pending |
| COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDSA61K 31/7008, C12N 15/1138, A61K 47/549, A61K 9/0031, A61K 9/0053, A61K 31/7105, A61K 31/7115, A61K 31/712, A61K 31/713, A61K 47/12, C12N 15/113, C12N 15/1137, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/3341, C12N2310/341, C12N2310/346, C12N2310/351, C12N2310/3515, C12N2320/32, C12N2320/51, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2026-01-23Thazha P. Prakash | pending |
| COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSIONA61K 31/712, A61K 48/00, C12N 15/113, C12N 15/1136, A61P 9/12, A61K 31/7088, C07H 21/00, C07H 21/02, C07H 21/04, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/316, C12N2310/32, C12N2310/322, C12N2310/3341, C12N2310/351, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2026-01-21Adam MULLICK | pending |
| Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) PopulationsA61K 31/7088, A61K 48/00, A61K 48/005, C12N 15/113, A61P 43/00, A61P 3/00, A61P 9/00, A61P 1/18, A61P 3/06, A61K 39/395, A61K 45/06, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3341, C12N2310/341, C12N2310/346, C12N2310/3525, C12N2320/30Filed as Ionis Pharmaceuticals, Inc.2026-01-13Veronica J. ALEXANDER | pending |
| COMPOUNDS AND METHODS FOR MODULATING HNRNPH2 EXPRESSIONFiled as IONIS PHARMACEUTICALS, INC.2026-01-08SUSAN M. FREIER | pending |
| CD29 Targeted Oligonucleotides and Uses ThereofC12N 15/1137, C07K 16/2842, C12N2310/113, C12N2310/14, C12N2310/314, C12N2310/315, C12N2310/3231, C12N2310/3513Filed as Ionis Pharmaceuticals, Inc.2025-12-19Lulu Huang | pending |
| LIPID ENCAPSULATED NANOPARTICLESFiled as IONIS PHARMACEUTICALS, INC.2025-12-09THAZHA P. PRAKASH | pending |
| COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSIONA61K 47/549, A61K 31/7125, C12N 15/113, A61K 47/59, A61P 43/00, A61P 3/00, A61P 9/00, A61P 25/00, A61K 31/7088, A61K 31/7105, A61K 31/713, A61K 48/00, C07H 21/00, C07H 21/04, C12N 15/111, C12N 15/1137, C12N2310/11, C12N2310/113, C12N2310/14, C12N2310/17, C12N2310/31, C12N2310/315, C12N2310/32, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/3341, C12N2310/34, C12N2310/341, C12N2310/346, C12N2310/35, C12N2310/351, C12N2310/3511, C12N2310/3513, C12N2310/3515, C12N2310/3525, C12N2310/353, C12N2320/32, C12Y 301/03048Filed as IONIS PHARMACEUTICALS, INC.2025-12-04Thazha P. PRAKASH | pending |
| METHODS FOR SAFELY REDUCING THROMBOPOIETINA61K 31/7115, A61P 7/02, A61P 35/00, A61K 31/712, A61K 45/06, C12N 15/1136, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/3341, C12N2310/341, C12N2320/11, C12N2320/30, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2025-11-17Andras Gruber | pending |
| Sugar Modified Oligonucleotides and Uses ThereofC12N 15/113, C12N 15/85, A61K 47/549, A61P 43/00, A61K 31/7105, A61K 31/712, C07H 21/02, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/531, C12N2830/50, C12N2310/3533, C12N2310/3525, C12N2310/3521Filed as Ionis Pharmaceuticals, Inc.2025-10-31Mehran Nikan | pending |
| COMPOUNDS AND METHODS FOR REDUCING PACS1 EXPRESSIONFiled as IONIS PHARMACEUTICALS, INC.2025-09-30HOLLY KORDASIEWICZ | pending |
| COMPOUNDS AND METHODS FOR MODULATING ALPHA-SYNUCLEIN EXPRESSIONFiled as IONIS PHARMACEUTICALS, INC.2025-08-20HIEN THUY ZHAO | pending |
| PATTERNED MODIFIED OLIGONUCLEOTIDES FOR EXTENDED DURATION OF ACTIONFiled as IONIS PHARMACEUTICALS, INC.2025-08-20HIEN THUY ZHAO | pending |
| Compounds and Methods for Reducing APP ExpressionFiled as Ionis Pharmaceuticals, Inc.2025-08-14Hien Thuy Zhao | pending |
| COMPOUNDS AND METHODS FOR MODULATING ALPHA-SYNUCLEIN EXPRESSIONFiled as Ionis Pharmaceuticals, Inc.2025-08-14Hien Thuy ZHAO | pending |
| Linkage Modified Oligomeric Compounds and Uses ThereofA61K 31/7105, C07H 21/00, C12N 15/113, A61K 47/549, A61P 39/00, A61K 31/015, A61K 31/7048, A61K 45/06, C07H 21/02, C12N2310/11, C12N2310/14, C12N2310/314, C12N2310/3145, C12N2310/315, C12N2310/321, C12N2310/323, C12N2310/3231, C12N2310/341, C12N2310/351, C12N2310/3515, C12N2320/32, C12N2320/51, C12N2320/53, C12N2330/30, C12N2310/322, C12N2310/3533, C12N2310/3521, C12N2310/3525, A61K 31/352, A61K2300/00, A61K 31/05Filed as Ionis Pharmaceuticals, Inc.2025-08-13Brooke A. Anderson | pending |
| CELL-TARGETING COMPLEXES AND USES THEREOFFiled as IONIS PHARMACEUTICALS, INC.2025-08-12MICHAEL TANOWITZ | pending |
| Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) PopulationsA61K 31/7088, A61K 48/00, A61K 48/005, C12N 15/113, A61P 43/00, A61P 3/00, A61P 9/00, A61P 1/18, A61P 3/06, A61K 39/395, A61K 45/06, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3341, C12N2310/341, C12N2310/346, C12N2310/3525, C12N2320/30Filed as Ionis Pharmaceuticals, Inc.2025-08-11Veronica J. ALEXANDER | pending |
| MODULATING APOLIPOPROTEIN (A) EXPRESSIONA61K 31/7125, C12N 15/113, A61P 3/00, A61P 9/00, A61P 3/06, A61J 1/05, A61K 9/0019, A61K 9/08, A61K 31/7088, A61K 48/00, C07K 14/775, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/341, C12N2310/351, C12N2310/3515, C12N2310/3525, C12N2320/32, C12N2320/35Filed as Ionis Pharmaceuticals, Inc.2025-08-06Nicholas J. VINEY | pending |
| Compositions and Methods for Treating and Preventing Prekallikrein-Associated ConditionsA61K 31/7088, A61K 48/00, C12N 15/1137, A61P 7/10, A61P 27/02, C12N2310/11, C12N2310/315, C12N2310/322, C12N2310/3341, C12N2310/341, C12N2310/345, C12N2310/346, C12N2310/3515, C12Y 304/21034, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2025-07-16Eugene SCHNEIDER | pending |
| COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSIONA61P 9/00, C12N 15/113, C12N 15/1138, A61K 47/542, A61K 47/64, A61P 9/04, A61K 31/713, C12N2310/11, C12N2310/14, C12N2310/313, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/323, C12N2310/3341, C12N2310/341, C12N2310/343, C12N2310/344, C12N2310/3513, C12N2310/3515, C12N2310/3521, C12N2310/3525, C12N2310/3531, C12N2310/3533, C12N2320/32Filed as Ionis Pharmaceuticals, Inc.2025-07-14Dieter A. KUBLI | 12624358 |
| MODIFIED OLIGONUCLEOTIDESFiled as IONIS PHARMACEUTICALS, INC.2025-07-11Graeme C. Freestone | pending |
| Compositions and Methods for Modulating Complement Factor B ExpressionC12N 5/00, C12N 15/113, C12N 15/1137, A61K 47/555, A61P 27/02, A61P 37/02, A61P 43/00, A61P 13/12, A61K 31/7088, A61K 38/00, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/3341, C12N2310/341, C12N2310/346, C12N2310/351, C12N2310/3525, C12Q 1/68, C12Y 304/21047Filed as Ionis Pharmaceuticals, Inc.2025-06-30Thazha P. Prakash | pending |
| Compounds and Methods for Reducing KCNT1 ExpressionC12N 15/113, C12N 15/1138, A61P 25/24, A61P 25/08, A61K 31/7088, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/3341, C12N2310/341, C12N2310/346, C12N2310/351, C12N2310/3525, C12N2320/11, C12N2320/32Filed as Ionis Pharmaceuticals, Inc.2025-06-27Huynh-Hoa Bui | pending |
| LIPID ENCAPSULATED NANOPARTICLESFiled as Ionis Pharmaceuticals, Inc.2025-06-10Thazha P. Prakash | pending |
| METHODS AND COMPOSITIONS FOR REDUCING DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)Filed as IONIS PHARMACEUTICALS, INC.2025-06-05SANJAY BHANOT | pending |
| Compounds and Methods for Reducing ATXN3 ExpressionA61K 31/7115, C12N 15/1137, A61P 25/14, A61P 25/28, A61K 31/7088, A61K 31/7125, C12N 15/113, C12N2310/11, C12N2310/315, C12N2310/3181, C12N2310/321, C12N2310/3341, C12N2310/341, C12N2310/346, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2025-06-05Susan M. Freier | pending |
| COMPOSITIONS AND METHODS FOR MODULATING MECP2 EXPRESSIONA61P 25/22, A61K 31/712, C12N 15/113, C12N2310/11, C12N2310/315, C12N2310/3231, C12N2310/3341, C12N2310/341, C12N2310/346Filed as Ionis Pharmaceuticals, Inc.2025-05-30Susan M. Freier | pending |
| LINKAGE MODIFIED OLIGOMERIC AGENTS AND USES THEREOFFiled as IONIS PHARMACEUTICALS, INC.2025-05-30W. BRAD WAN | pending |
| Methods for Deprotecting and Purifying Oligonucleotide CompoundsB01D 71/10, C12N 15/113, B01D 69/02, C07H 1/06, C07H 15/00, C12N 15/1017, C12N 15/11, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3341, C12N2310/351Filed as Ionis Pharmaceuticals, Inc.2025-05-19Dana Chreng | pending |
| COMPOUNDS AND METHODS FOR MODULATING APOE EXPRESSIONC07H 21/04, A61K 31/7125Filed as Ionis Pharmaceuticals, Inc.2025-05-16Eric E. Swayze | pending |
| PATTERNED DOUBLE STRANDED OLIGONUCLEOTIDESFiled as IONIS PHARMACEUTICALS, INC.2025-05-16REBECCA J.B. SCHAFER | pending |
| COMPOUNDS AND METHODS FOR MODULATING APOE EXPRESSIONFiled as IONIS PHARMACEUTICALS, INC.2025-05-16HIEN THUY ZHAO | pending |
| PATTERNED MODIFIED OLIGONUCLEOTIDESFiled as IONIS PHARMACEUTICALS, INC.2025-05-16MICHAEL T. MIGAWA | pending |
| Linkage Modified Oligomeric CompoundsC12N 15/113, A61K 45/06, C12N2310/315, C12N2310/321, C12N2310/3341, C12N2310/341, C12N2310/345, C12N2310/351, A61K 47/549, C07H 21/00, C12N 15/111, C12N 15/1136, C12N2310/11, C12N2310/312, C12N2310/314, C12N2310/3181, C12N2310/3183, C12N2310/3231, C12N2310/346, C12N2320/50Filed as Ionis Pharmaceuticals, Inc.2025-05-12Michael T. Migawa | pending |
| COMPOUNDS AND METHODS FOR MODULATING SMN2A61K 31/712, A61K 31/713, C12N 15/113, A61P 25/28, A61K 31/7125, A61K 48/00, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3341, C12N2310/345, C12N2310/346, C12N2310/3515, C12N2320/33, C12N2310/3521, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2025-05-02Frank Rigo | pending |
| Methods for Modulating Complement Factor B ExpressionA61P 13/12, A61K 31/519, A61K 31/7125, A61P 27/02, A61P 37/06, A61K 9/0019, A61K 9/0048, A61K 9/0051, A61K 9/0053, A61K 9/4858, A61K 31/19, A61K 31/353, A61K 31/357, A61K 31/501, A61K 31/554, A61K 31/70, A61K 45/06, C12N 15/1137, C12N2310/11, C12N2310/315, C12N2310/322, C12N2310/3341, C12N2310/341, C12N2310/351, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2025-05-02Daniel A. Norris | pending |
| METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSIONA61K 31/7115, A61K 31/712, A61K 31/7125, C12N 15/111, C12N 15/113, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/323, C12N2310/3231, C12N2310/3341, C12N2310/3525, C12N2320/50, C12N2320/51, C12N2320/52Filed as Ionis Pharmaceuticals, Inc.2025-03-27Rosanne M. Crooke | pending |
| COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSIONA61K 47/549, A61K 31/7125, C12N 15/113, A61K 47/59, A61P 43/00, A61P 3/00, A61P 9/00, A61P 25/00, A61K 31/7088, A61K 31/7105, A61K 31/713, A61K 48/00, C07H 21/00, C07H 21/04, C12N 15/111, C12N 15/1137, C12N2310/11, C12N2310/113, C12N2310/14, C12N2310/17, C12N2310/31, C12N2310/315, C12N2310/32, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/3341, C12N2310/34, C12N2310/341, C12N2310/346, C12N2310/35, C12N2310/351, C12N2310/3511, C12N2310/3513, C12N2310/3515, C12N2310/3525, C12N2310/353, C12N2320/32, C12Y 301/03048Filed as Ionis Pharmaceuticals, Inc.2025-03-24Thazha P. PRAKASH | pending |
| Conjugated Antisense Compounds and Their UseA61K 31/713, C12N 15/1137, A61K 47/554, A61K 9/0085, C12N 15/113, C12N 15/63, C12N2310/11, C12N2310/113, C12N2310/14, C12N2310/31, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/3341, C12N2310/341, C12N2310/351, C12N2310/3515, C12N2310/3535, C12N2310/531, C12N2320/32, C12Y 207/11001, C12N2310/3521Filed as Ionis Pharmaceuticals, Inc.2025-03-18Michael Oestergaard | pending |
| POLYPEPTIDES AND USES THEREOFFiled as Ionis Pharmaceuticals, Inc.2025-03-13Jing Zhao | pending |
| MODIFIED OLIGONUCLEOTIDESFiled as IONIS PHARMACEUTICALS, INC.2025-03-13Graeme C. Freestone | pending |
| COMPOUNDS AND METHODS FOR REDUCING PRION EXPRESSIONC12N 15/113, C12N 15/1131, C12N2310/20, A61P 25/28, A61P 31/14, A61P 25/00, A61P 25/16, C12N 9/226, A61K 31/7088, A61K 31/7105, C07H 21/00, C07H 21/02, C12N2310/11, C12N2310/14, C12N2310/31, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/3341, C12N2310/34, C12N2310/341, C12N2310/351, C12N2320/32, C12N2320/35, C12N2310/3521Filed as Ionis Pharmaceuticals, Inc.2025-02-06Susan M. Freier | pending |
| MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)C12N 15/1137, A61P 1/16, C07H 21/00, C12N2310/11, C12N2310/315, C12N2310/3341, C12N2310/341, C12N2310/346, C12N2320/35, C12Y 203/0102, C12N2310/321, C12N2310/3525, C12N 15/113Filed as Ionis Pharmaceuticals, Inc.2025-02-03Sanjay Bhanot | pending |
| COMPOUNDS AND METHODS FOR MODULATING SCN2AA61K 31/7088, C12N 15/113, C12N 15/1138, A61P 25/00, A61P 25/08, A61K 31/712, A61K 48/00, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/3341, C12N2310/341, C12N2310/344, C12N2310/3525Filed as Ionis Pharmaceuticals, Inc.2025-01-15Paymaan Jafar-Nejad | pending |
| Selective Antisense Compounds and Uses ThereofC12N 15/113, C12N 15/111, C12N2310/11, C12N2310/312, C12N2310/3125, C12N2310/315, C12N2310/316, C12N2310/321, C12N2310/3231, C12N2310/3341, C12N2310/341, C12N2310/351, C12N2320/34Filed as Ionis Pharmaceuticals, Inc.2025-01-14Punit P. Seth | pending |
| Conjugated Antisense Compounds for Use in TherapyA61K 31/712, A61P 3/06, A61K 9/0019, A61K 48/0016, A61K 48/005, A61K 48/0083, C07H 19/20, C07H 21/00, C07H 21/02, C07H 21/04, C12N 15/113, C12N2310/341, C12N2310/3515Filed as Ionis Pharmaceuticals, Inc.2025-01-14Nicholas J. Viney | pending |
| COMPOUNDS AND METHODS FOR MODULATING HNRNPH2 EXPRESSIONFiled as Ionis Pharmaceuticals, Inc.2025-01-09Susan M. Freier | pending |
| Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses ThereofC12N 15/111, C12N 15/113, C12N2310/11, C12N2310/315, C12N2310/3231, C12N2310/341, C12N2310/345, C12N2310/346, C12N2310/3525, C12N2320/50, C12N2310/322, C12N2310/3531, C12N2310/3533, C12N2310/321, C12N2310/3521Filed as Ionis Pharmaceuticals, Inc.2025-01-09Susan M. Freier | pending |
| NUCLEIC ACID BINDING AGENTS AND USES THEREOFFiled as IONIS PHARMACEUTICALS, INC.2024-12-20JING ZHAO | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on IONS
Company overviewEverything on IONS in one place, with the price.SEC filingsWhat IONS's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat IONS's own officers and directors buy and sell.Executive payWhat IONS awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in IONS.Funds holding itWhich funds and ETFs hold IONS, and how big a bet.LobbyingWhat IONS spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on IONS's account, and who they worked for.